Cargando…
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial)
INTRODUCTION: Progestin therapy is the only fertility-sparing treatment option for patients with atypical endometrial hyperplasia (AEH) and endometrial cancer (EC). However, the results of three meta-analyses revealed a high remission rate, as well as an association with a high rate of relapse. We p...
Autores principales: | Mitsuhashi, Akira, Kawasaki, Yohei, Hori, Makoto, Fujiwara, Tadami, Hanaoka, Hideki, Shozu, Makio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050341/ https://www.ncbi.nlm.nih.gov/pubmed/32114477 http://dx.doi.org/10.1136/bmjopen-2019-035416 |
Ejemplares similares
-
Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer
por: Gu, Wenjing, et al.
Publicado: (2022) -
Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019) -
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
por: Zhao, Xin, et al.
Publicado: (2022) -
Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia
por: Behnamfar, Fariba, et al.
Publicado: (2014) -
Inhibitory Effects of Medroxyprogesterone Acetate on Mouse Endometrial Carcinogenesis
por: Niwa, Kenji, et al.
Publicado: (1995)